A model of anticholinergic activity of atypical antipsychotic medications

Schizophrenia Research

Volumn 88, Issue 1-3, 2006, Pages 63-72

  Chew, Marci L ^a,b   Mulsant, Benoit H ^b,c,d   Pollock, Bruce G ^b,c,d,e   Lehman, Mark E ^f   Greenspan, Andrew ^g   Kirshner, Margaret A ^b   Bies, Robert R ^a,b   Kapur, Shitij ^c,d   Gharabawi, Georges ^h  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ROTMAN RESEARCH INSTITUTE   (Canada)

^f Ortho McNeil Pharmaceutical Incorporated   (United States)

^g JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anticholinergic; Atypical antipsychotic; Cognition; Muscarinic receptor; Psychopharmacology; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATROPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANTICHOLINERGIC EFFECT; ARTICLE; COGNITION; DOSE RESPONSE; IN VITRO STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RADIORECEPTOR ASSAY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BINDING SITES; CLOZAPINE; COGNITION DISORDERS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; QUINOLONES; RECEPTORS, CHOLINERGIC; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES;

EID: 33750628479     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.07.011     Document Type: Article

References (67)

1. Aaltonen L., Syvalahti E., Iisalo E., and Peltomaki T. Anticholinergic activity in the serum of patients receiving maintenance amitriptyline or doxepin therapy. Acta Pharmacol. Toxicol. 56 (1985) 75-80
2. Alexopoulos G.S., Streim J., Carpenter D., and Docherty J.P. Using antipsychotic agents in older patients. J. Clin. Psychiatry 65 Suppl 2 (2004) 5-104
3. Aripiprazole, package insert, 2005. Bristol-Meyers Squibb Company and Otsuka America Pharmaceutical, Inc. (Revised April 2005).
4. Barak Y., Wittenberg N., Naor S., Kutzuk D., and Weizman A. Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr. Psychiatry 40 (1999) 320-325
5. Bolden C., Cusack B., and Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 260 (1992) 576-580
6. Bonner T.I., Buckley N.J., Young A.C., and Brann M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science 237 (1987) 527-532
7. Bymaster F.P., and Falcone J.F. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Eur. J. Pharmacol. 390 (2000) 245-248
8. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., and Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
9. Bymaster F.P., Felder C.C., Tzavara E., Nomikos G.G., Calligaro D.O., and McKinzie D.L. Muscarinic mechanisms of antipsychotic atypicality. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 (2003) 1125-1143
10. Bymaster F.P., McKinzie D.L., Felder C.C., and Wess J. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem. Res. 28 (2003) 437-442
11. Callaghan J.T., Bergstrom R.F., Ptak L.R., and Beasley C.M. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37 (1999) 177-193
12. Caulfield M.P. Murscarinic receptors-characterization, coupling and function. Pharmacol. Ther. 58 (1993) 319-379
13. Chengappa K.N., Pollock B.G., Parepally H., Levine J., Kirshner M.A., Brar J.S., and Zoretich R.A. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J. Clin. Psychopharmacol. 20 (2000) 311-316
14. Chew M.L., Mulsant B.H., and Pollock B.G. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am. J. Geriatr. Psychiatry 13 (2005) 535-538
15. Clozapine, package insert, 2005. Novartis Pharmaceuticals Cooperation (revised May 2005).
16. de Leon J., Odom-White A., Josiassen R.C., Diaz F.J., Cooper T.B., and Simpson G.M. Serum antimuscarinic activity during clozapine treatment. J. Clin. Psychopharmacol. 23 (2003) 336-341
17. Felder C.C., Porter A.C., Skillman T.L., Zhang L., Bymaster F.P., Nathanson N.M., Hamilton S.E., Gomeza J., Wess J., and McKinzie D.L. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 68 (2001) 2605-2613
18. Flacker J.M., and Lipsitz L.A. Serum anticholinergic activity changes with acute illness in elderly medical patients. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 54 (1999) M12-M16
19. Flynn D.D., Ferrari-DiLeo G., Mash D.C., and Levey A.I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. 64 (1995) 1888-1891
20. Gardner D.M., Baldessarini R.J., and Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 172 (2005) 1703-1709
21. Gex-Fabry M., Balant-Gorgia A.E., and Balant L.P. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther. Drug Monit. 25 (2003) 46-53
22. Gomeza J., Zhang L., Kostenis E., Felder C., Bymaster F., Brodkin J., Shannon H., Xia B., Deng C., and Wess J. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10483-10488
23. Goodnick P.J., and Jerry J.M. Aripiprazole: profile on efficacy and safety. Expert Opin. Pharmacother. 3 (2002) 1773-1781
24. Hamilton S.E., Hardouin S.N., Anagnostaras S.G., Murphy G.G., Richmond K.N., Silva A.J., Feigl E.O., and Nathanson N.M. Alteration of cardiovascular and neuronal function in M1 knockout mice. Life Sci. 68 (2001) 2489-2493
25. Hitri A., Craft R.B., Fallon J., Sethi R., and Sinha D. Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients. Psychopharmacol. Bull. 23 (1987) 33-37
26. Huang F., Lasseter K.C., Janssens L., Verhaeghe T., Lau H., and Zhao Q. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J. Clin. Pharmacol. 42 (2002) 1341-1351
27. Ichikawa J., Chung Y.C., Li Z., Dai J., and Meltzer H.Y. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res. 958 (2002) 176-184
28. Iisalo E., and Aaltonen L. Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy. Br. J. Clin. Pharmacol. 17 (1984) 325-329
29. Jaskiw G.E., Thyrum P.T., Fuller M.A., Arvanitis L.A., and Yeh C. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Clin. Pharmacokinet. 43 (2004) 1025-1035
30. Jerusalinsky D., Kornisiuk E., Alfaro P., Quillfeldt J., Alonso M., Verde E.R., Cervenansky C., and Harvey A. Muscarinic toxin selective for m4 receptors impairs memory in the rat. NeuroReport 9 (1998) 1407-1411
31. Johnstone E.C., Crow T.J., Ferrier I.N., Frith C.D., Owens D.G., Bourne R.C., and Gamble S.J. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol. Med. 13 (1983) 513-527
32. Katz I.R., Greenberg W.M., Barr G.A., Garbarino C., Buckley P., and Smith D. Screening for cognitive toxicity of anticholinergic drugs. J. Clin. Psychiatry 46 (1985) 323-326
33. Lachowicz J.E., Duffy R.A., Ruperto V., Kozlowski J., Zhou G., Clader J., Billard W., Binch III H., Crosby G., Cohen-Williams M., Strader C.D., and Coffin V. Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788. Life Sci. 68 (2001) 2585-2592
34. 123I]-IDEX SPECT study. Psychopharmacology (Berl.) 156 (2001) 53-57
35. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
36. Mallikaarjun S., Salazar D.E., and Bramer S.L. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol. 44 (2004) 179-187
37. Matsui M., Yamada S., Oki T., Manabe T., Taketo M.M., and Ehlert F.J. Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sci. 75 (2004) 2971-2981
38. Mauri M.C., Laini V., Boscati L., Rudelli R., Salvi V., Orlandi R., and Papa P. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur. Psychiatr. 16 (2001) 57-63
39. Miller P.S., Richardson J.S., Jyu C.A., Lemay J.S., Hiscock M., and Keegan D.L. Association of low serum anticholinergic levels and cognitive impairment in elderly presurgical patients. Am. J. Psychiatry 145 (1988) 342-345
40. Minzenberg M.J., Poole J.H., Benton C., and Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 161 (2004) 116-124
41. Mirza N.R., Peters D., and Sparks R.G. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 9 (2003) 159-186
42. Mulsant B.H., Pollock B.G., Kirshner M., Shen C., Dodge H., and Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch. Gen. Psychiatry 60 (2003) 198-203
43. Mulsant B.H., Gharabawi G.M., Bossie C.A., Mao L., Martinez R.A., Tune L.E., Greenspan A.J., Bastean J.N., and Pollock B.G. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J. Clin. Psychiatry 65 (2004) 1708-1714
44. Nebes R.D., Pollock B.G., Mulsant B.H., Kirshner M.A., Halligan E., Zmuda M., and Reynolds III C.F. Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients. Psychopharmacol. Bull. 33 (1997) 715-720
45. Olanzapine, package insert, 2005. Eli Lilly and Company (revised May 2005).
46. Perlick D., Stastny P., Katz I., Mayer M., and Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia. Am. J. Psychiatry 143 (1986) 230-232
47. Quetiapine, package insert, 2005. AstraZeneca Pharmaceuticals LP.
48. Raedler T.J., Knable M.B., Jones D.W., Lafargue T., Urbina R.A., Egan M.F., Pickar D., and Weinberger D.R. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 23 (2000) 56-68
49. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Egan M.F., and Weinberger D.R. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 28 (2003) 1531-1537
50. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry 60 Suppl 10 (1999) 5-14
51. Richelson E., and Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68 (2000) 29-39
52. Risperidone, package insert, 2005. Janssen Pharmaceutica Products L.P. (revised May 2005).
53. Rostami-Hodjegan A., Amin A.M., Spencer E.P., Lennard M.S., Tucker G.T., and Flanagan R.J. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J. Clin. Psychopharmacol. 24 (2004) 70-78
54. Schmidt A.W., Lebel L.A., Howard Jr. H.R., and Zorn S.H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 425 (2001) 197-201
55. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
56. Strauss M.E., Reynolds K.S., Jayaram G., and Tune L.E. Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res. 3 (1990) 127-129
57. Tandon R., and Jibson M.D. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann. Clin. Psychiatry 14 (2002) 123-129
58. Tice M.A., Hashemi T., Taylor L.A., and McQuade R.D. Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age. Brain Res. Dev. Brain Res. 92 (1996) 70-76
59. Tracy J.I., Monaco C.A., Abraham G., Josiassen R.C., and Pollock B.G. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J. Clin. Psychiatry 59 (1998) 184-188
60. Tracy J.I., Monaco C., Giovannetti T., Abraham G., and Josiassen R.C. Anticholinergicity and cognitive processing in chronic schizophrenia. Biol. Psychol. 56 (2001) 1-22
61. Tune L., and Coyle J.T. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch. Gen. Psychiatry 37 (1980) 293-297
62. Tune L., and Coyle J.T. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology (Berl.) 75 (1981) 9-15
63. Tune L.E., Strauss M.E., Lew M.F., Breitlinger E., and Coyle J.T. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry 139 (1982) 1460-1462
64. Veroff A.E., Bodick N.C., Offen W.W., Sramek J.J., and Cutler N.R. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis. Assoc. Disord. 12 (1998) 304-312
65. Wilner K.D., Tensfeldt T.G., Baris B., Smolarek T.A., Turncliff R.Z., Colburn W.A., and Hansen R.A. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br. J. Clin. Pharmacol. 49 Suppl 1 (2000) 15S-20S
66. Wong Y.W., Yeh C., and Thyrum P.T. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J. Clin. Psychopharmacol. 21 (2001) 89-93
67. Ziprasidone, package insert, 2005. Pfizer, Inc. (revised May 2005).